Literature DB >> 16790586

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.

Jeffrey A Zonder, Bart Barlogie, Brian G M Durie, Jason McCoy, John Crowley, Mohamad A Hussein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16790586     DOI： 10.1182/blood-2006-01-0154

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  29 in total

1.  An unusual cause for an optic disc haemorrhage.

Authors:  Julia Baxter; Anusha Kailasanathan; Hean Chen
Journal:  BMJ Case Rep       Date:  2011-02-14

2.  Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).

Authors:  Jeffrey A Zonder; John Crowley; Mohamad A Hussein; Vanessa Bolejack; Dennis F Moore; Brock F Whittenberger; Muneer H Abidi; Brian G M Durie; Bart Barlogie
Journal:  Blood       Date:  2010-09-27       Impact factor: 22.113

3.  Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.

Authors:  Sigurdur Y Kristinsson; Ruth M Pfeiffer; Magnus Björkholm; Lynn R Goldin; Sam Schulman; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

4.  Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.

Authors:  Atsushi Isoda; Naru Sato; Yuri Miyazawa; Yoshinobu Matsumoto; Mina Koumoto; Masahito Ookawa; Morio Sawamura; Morio Matsumoto
Journal:  Int J Hematol       Date:  2015-07-16       Impact factor: 2.490

Review 5.  Molecular biology for formyl peptide receptors in human diseases.

Authors:  Yongsheng Li; Duyun Ye
Journal:  J Mol Med (Berl)       Date:  2013-02-13       Impact factor: 4.599

6.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authors:  Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

Review 7.  International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

Authors:  Antonio Palumbo; S Vincent Rajkumar; Jesus F San Miguel; Alessandra Larocca; Ruben Niesvizky; Gareth Morgan; Ola Landgren; Roman Hajek; Hermann Einsele; Kenneth C Anderson; Meletios A Dimopoulos; Paul G Richardson; Michele Cavo; Andrew Spencer; A Keith Stewart; Kazuyuki Shimizu; Sagar Lonial; Pieter Sonneveld; Brian G M Durie; Philippe Moreau; Robert Z Orlowski
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

Review 8.  Thrombosis in multiple myeloma (MM).

Authors:  Gabriela Cesarman-Maus; Esteban Braggio; Rafael Fonseca
Journal:  Hematology       Date:  2012-04       Impact factor: 2.269

Review 9.  Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma.

Authors:  Gordon F Rushworth; Stephen J Leslie; Peter Forsyth; Claire Vincent
Journal:  Ther Adv Drug Saf       Date:  2012-06

10.  Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.

Authors:  Christine Chen; Donna E Reece; David Siegel; Ruben Niesvizky; Ralph V Boccia; Edward A Stadtmauer; Rafat Abonour; Paul Richardson; Jeffrey Matous; Shaji Kumar; Nizar J Bahlis; Melissa Alsina; Robert Vescio; Steven E Coutre; Dennis Pietronigro; Robert D Knight; Jerome B Zeldis; Vincent Rajkumar
Journal:  Br J Haematol       Date:  2009-05-26       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.